Non-Invasive Chromosomal Evaluation of 22q11.2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

420 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2020-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NIPD on cffDNA for Triplet Repeat Diseases

NCT04698551

Myotonic Dystrophy 1 Huntington Disease Fragile X Syndrome

UNKNOWN

Hematological Disorders in Patients With GI Angiodysplasia

NCT07183995

GI Bleeding

NOT_YET_RECRUITING

The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients

NCT00173095

Spontaneous Subarachnoid Hemorrhage

UNKNOWN

CGH Array in Bilateral Clubfoot

NCT04737083

Clubfoot Prenatal Disorder

UNKNOWN

Renal HYPODYSPLASIA : Genetic and Familial Assessment

NCT00925379

Renal HYPODYSPLASIA, Nonsyndromic, 1

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

22q.11.2 Deletion/Duplication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Confirmed 22q.11.2 deletion/duplication

No interventions assigned to this group

Suspected 22q.11.2 deletion/duplication

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is ≥18 years of age and able to provide consent or, if under the age of 18, the patient has parental consent and child assent provided as required by the governing ethics committee.
2. If pregnant, patients must have a singleton pregnancy and be at least 10 weeks gestation at the time of the study blood draw.
3. Patients must meet at least one of the following conditions at the time of enrollment:

1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period;
2. are pregnant with fetal ultrasound findings consistent with a 22q11.2 deletion/duplication phenotype and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period;
3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed by genetic testing with documentation is available;
4. are biologically related parent of an enrolled child has chromosomal deletion/duplication in the region of 22q11.2;
4. If the site is selected to enroll control patients, they must be pregnant women undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication.

Exclusion Criteria

Patients meeting any of the following criteria will be excluded from the study:

1\. Patient has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes